Humanigen Inc (OTCQB:HGEN) announced Monday that longtime biotechnology executive and board of directors member Timothy Morris has joined its management team as both chief operating officer and chief financial officer, effective immediately.
Morris has worked as an executive at public biotechnology companies for more than two decades, most recently as CFO of Iovance Biotherapeutics Inc (NASDAQ:IOVA), a cancer immunotherapy company. While there, he oversaw the raising of more than $1 billion in equity, and over the course of his career he’s helped companies raise more than $2 billion in total.
Morris will be responsible for manufacturing and supply chain, corporate and business development, investor and public relations and human resources, in addition to his CFO duties, the company said. He joins Humanigen as the company is working to advance its drug lenzilumab as a treatment for coronavirus (COVID-19)
READ: Humanigen says lenzilumab selected for National Institute of Health's upcoming coronavirus clinical trial
“I am honored to join the Humanigen management team and look forward to helping advance our pivotal Phase III clinical trial for lenzilumab in COVID-19 patients as we plan for registration and potential commercialization, as well as continue to accelerate our deep pipeline,” Morris said in a statement.
Morris has been a member of Humanigen’s board of directors since 2016, but he has resigned that position in conjunction with his appointment.
“We are delighted that Tim has joined our leadership team at such an important time for the company,” CEO Cameron Durrant added. “We believe that his track record of accomplishments, combined with his capital markets expertise and extensive knowledge of the company, will be indispensable as Humanigen prepares for its next phase of growth as a potential commercial organization.”
Lenzilumab is designed to treat the cytokine storm, an overactive immune system response to conditions such as the coronavirus that can cause fever and inflammation and potentially lead to organ failure.
Separately, Humanigen also said it will host an investor call and webcast to discuss the National Institute of Health's selection of lenzilumab, the company's proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, as an agent in the NIAID-sponsored Big Effect Trial (BET) in hospitalized patients with coronavirus at 4:30 pm ET on Monday.
To participate, investors can dial toll free (833) 714-0938 or toll number +1 (778) 560-2680. The conference ID number is 1154357. A simultaneous webcast of the call and presentation can be accessed here. A replay of the webcast will be available on the company's website for 30 days following the event.
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel